Literature DB >> 33428889

YAP1 and its fusion proteins in cancer initiation, progression and therapeutic resistance.

Frank Szulzewsky1, Eric C Holland2, Valeri Vasioukhin3.   

Abstract

YAP1 is a transcriptional co-activator whose activity is controlled by the Hippo signaling pathway. In addition to important functions in normal tissue homeostasis and regeneration, YAP1 has also prominent functions in cancer initiation, aggressiveness, metastasis, and therapy resistance. In this review we are discussing the molecular functions of YAP1 and its roles in cancer, with a focus on the different mechanisms of de-regulation of YAP1 activity in human cancers, including inactivation of upstream Hippo pathway tumor suppressors, regulation by intersecting pathways, miRNAs, and viral oncogenes. We are also discussing new findings on the function and biology of the recently identified family of YAP1 gene fusions, that constitute a new type of activating mutation of YAP1 and that are the likely oncogenic drivers in several subtypes of human cancers. Lastly, we also discuss different strategies of therapeutic inhibition of YAP1 functions.
Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cancer; Gene fusions; Hippo signaling pathway; YAP1; YAP1 fusion

Mesh:

Substances:

Year:  2021        PMID: 33428889      PMCID: PMC8107117          DOI: 10.1016/j.ydbio.2020.12.018

Source DB:  PubMed          Journal:  Dev Biol        ISSN: 0012-1606            Impact factor:   3.148


  263 in total

Review 1.  c-Src, receptor tyrosine kinases, and human cancer.

Authors:  J S Biscardi; D A Tice; S J Parsons
Journal:  Adv Cancer Res       Date:  1999       Impact factor: 6.242

2.  Thyroid development in zebrafish lacking Taz.

Authors:  Andrea Pappalardo; Immacolata Porreca; Luigi Caputi; Elena De Felice; Stephan Schulte-Merker; Mariastella Zannini; Paolo Sordino
Journal:  Mech Dev       Date:  2015-10-22       Impact factor: 1.882

3.  Mutual interaction between YAP and c-Myc is critical for carcinogenesis in liver cancer.

Authors:  Weifan Xiao; Jiayi Wang; Chao Ou; Yue Zhang; Lifang Ma; Wenhao Weng; Qiuhui Pan; Fenyong Sun
Journal:  Biochem Biophys Res Commun       Date:  2013-08-28       Impact factor: 3.575

4.  Yes-associated protein (YAP65) is a proline-rich phosphoprotein that binds to the SH3 domain of the Yes proto-oncogene product.

Authors:  M Sudol
Journal:  Oncogene       Date:  1994-08       Impact factor: 9.867

5.  A gp130-Src-YAP module links inflammation to epithelial regeneration.

Authors:  Koji Taniguchi; Li-Wha Wu; Sergei I Grivennikov; Petrus R de Jong; Ian Lian; Fa-Xing Yu; Kepeng Wang; Samuel B Ho; Brigid S Boland; John T Chang; William J Sandborn; Gary Hardiman; Eyal Raz; Yoshihiko Maehara; Akihiko Yoshimura; Jessica Zucman-Rossi; Kun-Liang Guan; Michael Karin
Journal:  Nature       Date:  2015-02-25       Impact factor: 49.962

6.  MRTF potentiates TEAD-YAP transcriptional activity causing metastasis.

Authors:  Tackhoon Kim; Daehee Hwang; Dahye Lee; Jeong-Hwan Kim; Seon-Young Kim; Dae-Sik Lim
Journal:  EMBO J       Date:  2016-12-27       Impact factor: 11.598

7.  Loss of NF2/Merlin expression in advanced sporadic colorectal cancer.

Authors:  Tamara Cačev; Gorana Aralica; Božo Lončar; Sanja Kapitanović
Journal:  Cell Oncol (Dordr)       Date:  2013-12-10       Impact factor: 6.730

8.  Yes-associated protein 1 and transcriptional coactivator with PDZ-binding motif activate the mammalian target of rapamycin complex 1 pathway by regulating amino acid transporters in hepatocellular carcinoma.

Authors:  Yun-Yong Park; Bo Hwa Sohn; Randy L Johnson; Myoung-Hee Kang; Sang Bae Kim; Jae-Jun Shim; Lingegowda S Mangala; Ji Hoon Kim; Jeong Eun Yoo; Cristian Rodriguez-Aguayo; Sunila Pradeep; Jun Eul Hwang; Hee-Jin Jang; Hyun-Sung Lee; Rajesha Rupaimoole; Gabriel Lopez-Berestein; Woojin Jeong; Inn Sun Park; Young Nyun Park; Anil K Sood; Gordon B Mills; Ju-Seog Lee
Journal:  Hepatology       Date:  2015-11-26       Impact factor: 17.425

9.  Identification, mechanism of action, and antitumor activity of a small molecule inhibitor of hippo, TGF-β, and Wnt signaling pathways.

Authors:  Dipanjan Basu; Robert Lettan; Krishnan Damodaran; Susan Strellec; Miguel Reyes-Mugica; Abdelhadi Rebbaa
Journal:  Mol Cancer Ther       Date:  2014-04-02       Impact factor: 6.261

Review 10.  The Role of Merlin/NF2 Loss in Meningioma Biology.

Authors:  Sungho Lee; Patrick J Karas; Caroline C Hadley; James C Bayley V; A Basit Khan; Ali Jalali; Alex D Sweeney; Tiemo J Klisch; Akash J Patel
Journal:  Cancers (Basel)       Date:  2019-10-24       Impact factor: 6.639

View more
  15 in total

1.  Recurrent Fusion of the Genes for High-mobility Group AT-hook 2 (HMGA2) and Nuclear Receptor Co-repressor 2 (NCOR2) in Osteoclastic Giant Cell-rich Tumors of Bone.

Authors:  Ioannis Panagopoulos; Kristin Andersen; Ludmila Gorunova; Marius Lund-Iversen; Ingvild Lobmaier; Sverre Heim
Journal:  Cancer Genomics Proteomics       Date:  2022 Mar-Apr       Impact factor: 4.069

2.  Knowledge base and emerging trends in YAP1 research.

Authors:  Rong Xu; Zhiying Yang; Jiahui Fan; Xueying Huang; Linna Long; Siying Yu; Xiaorui Zhang; Xia Li; He Huang
Journal:  Am J Transl Res       Date:  2022-09-15       Impact factor: 3.940

3.  How Phosphofructokinase-1 Promotes PI3K and YAP/TAZ in Cancer: Therapeutic Perspectives.

Authors:  Luca Simula; Marco Alifano; Philippe Icard
Journal:  Cancers (Basel)       Date:  2022-05-18       Impact factor: 6.575

4.  Ependymoma associated protein Zfta is expressed in immature ependymal cells but is not essential for ependymal development in mice.

Authors:  Vicente Herranz-Pérez; Jin Nakatani; Masaki Ishii; Toshiaki Katada; Jose Manuel García-Verdugo; Shinya Ohata
Journal:  Sci Rep       Date:  2022-01-27       Impact factor: 4.379

5.  Hydrostatic Pressure Controls Angiogenesis Through Endothelial YAP1 During Lung Regeneration.

Authors:  Tadanori Mammoto; Tendai Hunyenyiwa; Priscilla Kyi; Kathryn Hendee; Kienna Matus; Sridhar Rao; Sang H Lee; Diana M Tabima; Naomi C Chesler; Akiko Mammoto
Journal:  Front Bioeng Biotechnol       Date:  2022-02-18

Review 6.  Potential Therapeutic Applications of N-Cadherin Antagonists and Agonists.

Authors:  Orest W Blaschuk
Journal:  Front Cell Dev Biol       Date:  2022-03-03

Review 7.  Recent Advances on Immunohistochemistry and Molecular Biology for the Diagnosis of Adnexal Sweat Gland Tumors.

Authors:  Nicolas Macagno; Pierre Sohier; Thibault Kervarrec; Daniel Pissaloux; Marie-Laure Jullie; Bernard Cribier; Maxime Battistella
Journal:  Cancers (Basel)       Date:  2022-01-18       Impact factor: 6.639

Review 8.  Molecular Classification and Therapeutic Targets in Ependymoma.

Authors:  Thomas Larrew; Brian Fabian Saway; Stephen R Lowe; Adriana Olar
Journal:  Cancers (Basel)       Date:  2021-12-10       Impact factor: 6.639

9.  MicroRNA-181a Regulates the Proliferation and Differentiation of Hu Sheep Skeletal Muscle Satellite Cells and Targets the YAP1 Gene.

Authors:  Mingliang He; Weibo Zhang; Shan Wang; Ling Ge; Xiukai Cao; Shanhe Wang; Zehu Yuan; Xiaoyang Lv; Tesfaye Getachew; Joram M Mwacharo; Aynalem Haile; Wei Sun
Journal:  Genes (Basel)       Date:  2022-03-16       Impact factor: 4.096

10.  Suppressive Effect of Autocrine FGF21 on Autophagy-Deficient Hepatic Tumorigenesis.

Authors:  Jinyoung Kim; Soyeon Lee; Myung-Shik Lee
Journal:  Front Oncol       Date:  2022-03-07       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.